IV Chelation Therapy vs. Oral Chelation: How to Evaluate Your Options

June 16, 2026; By Benjamin Kosubevsky

If you are researching chelation therapy in South Florida, one of the first decisions you will encounter is the choice between intravenous (IV) and oral chelation. Both approaches involve the use of chelating agents that bind to heavy metals in the body, but they differ meaningfully in delivery, clinical evidence, and practical considerations.

How Chelation Works

Chelation therapy uses specific chemical agents—such as EDTA (ethylenediaminetetraacetic acid), DMSA, or DMPS—that bind to heavy metals in the bloodstream, forming stable complexes that can be excreted by the kidneys. The concept is well-established in medical toxicology and has been used for decades in the treatment of acute heavy metal poisoning. A review published in the International Journal of Environmental Research and Public Health summarized chelation mechanisms and their clinical applications across various metal exposures (Flora & Pachauri, Int J Environ Res Public Health, 2010).

IV Chelation: The Clinical Evidence

IV EDTA chelation has the largest body of controlled clinical evidence. The Trial to Assess Chelation Therapy (TACT), funded by the National Institutes of Health and published in JAMA, was a randomized, double-blind, placebo-controlled trial enrolling 1,708 patients with prior myocardial infarction. The trial found a modest but statistically significant reduction in a composite cardiovascular endpoint in the chelation group, with a particularly pronounced benefit in the diabetic subgroup (Lamas et al., JAMA, 2013).

A subsequent analysis of the TACT diabetic subgroup, published in the Journal of the American Heart Association, found an even more substantial benefit—a 41% relative reduction in the primary endpoint among diabetic participants.

Oral Chelation: What to Know

Oral chelating agents (such as DMSA and DMPS) are available and used in some clinical settings. They offer the convenience of home administration. However, oral chelation has not been studied in a large-scale randomized trial comparable to TACT. Absorption through the gastrointestinal tract is variable, and the bioavailability of oral chelating agents may be lower than their IV counterparts. Gastrointestinal side effects are also more common with oral administration.

It is important to note that over-the-counter products marketed as “chelation supplements”—including certain clays, zeolites, and herbal formulations—are not supported by the same level of clinical evidence and should not be confused with medical chelation therapy.

Making the Decision

The choice between IV and oral chelation should be made in consultation with a physician who can evaluate your specific laboratory findings, exposure history, and clinical goals. At The Longevity Center FL in West Palm Beach, Dr. Kosubevsky offers IV EDTA chelation therapy for patients with documented heavy metal findings and discusses the evidence for each approach transparently.

Give Us a Call  +1 (561) 210-4033
Schedule a consultation at The Longevity Center FL in West Palm Beach. [Schedule an Appointment]

References

1. Lamas GA, Goertz C, Boineau R, et al. Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events: The TACT Randomized Trial. JAMA. 2013;309(12):1241-1250. [Full Text]
2. Flora SJ, Pachauri V. Chelation in Metal Intoxication. International Journal of Environmental Research and Public Health. 2010;7(7):2745-2788. [Full Text]